Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1007/s00280-011-1671-3 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/7WOS source URL
其它资讯
摘要Purpose PR-104 is activated by reductases under hypoxia or by aldo-keto reductase 1C3 (AKR1C3) to form cytotoxic nitrogen mustards. Hepatocellular carcinoma (HCC) displays extensive hypoxia and expresses AKR1C3. This study evaluated the safety and efficacy of PR-104 plus sorafenib in HCC.
着者Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ
期刊名称CANCER CHEMOTHERAPY AND PHARMACOLOGY
详细描述[Epub ahead of print].
出版年份2011
月份8
日期1
卷号68
期次2
出版社SPRINGER
页次539 - 545
国际标準期刊号0344-5http://aims.cuhk.edu.hk/converis/portal/Publication/704
语言英式英语
关键词AKR1C3; Hepatocellular carcinoma; PR-104; Sorafenib
Web of Science 学科类别Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY
